110 related articles for article (PubMed ID: 38016707)
1. Improving the mixed model for repeated measures to robustly increase precision in randomized trials.
Wang B; Du Y
Int J Biostat; 2023 Nov; ():. PubMed ID: 38016707
[TBL] [Abstract][Full Text] [Related]
2. Effect of heteroscedasticity between treatment groups on mixed-effects models for repeated measures.
Gosho M; Maruo K
Pharm Stat; 2018 Sep; 17(5):578-592. PubMed ID: 29978944
[TBL] [Abstract][Full Text] [Related]
3. A note on the bias of standard errors when orthogonality of mean and variance parameters is not satisfied in the mixed model for repeated measures analysis.
Maruo K; Ishii R; Yamaguchi Y; Doi M; Gosho M
Stat Med; 2020 Apr; 39(9):1264-1274. PubMed ID: 31916260
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bias-corrected covariance estimators for MMRM analysis in longitudinal data with dropouts.
Gosho M; Hirakawa A; Noma H; Maruo K; Sato Y
Stat Methods Med Res; 2017 Oct; 26(5):2389-2406. PubMed ID: 26265765
[TBL] [Abstract][Full Text] [Related]
6. The mixed model for repeated measures for cluster randomized trials: a simulation study investigating bias and type I error with missing continuous data.
Bell ML; Rabe BA
Trials; 2020 Feb; 21(1):148. PubMed ID: 32033617
[TBL] [Abstract][Full Text] [Related]
7. Analysis of covariance in randomized trials: More precision and valid confidence intervals, without model assumptions.
Wang B; Ogburn EL; Rosenblum M
Biometrics; 2019 Dec; 75(4):1391-1400. PubMed ID: 31009064
[TBL] [Abstract][Full Text] [Related]
8. Robustness of ANCOVA in randomized trials with unequal randomization.
Bartlett JW
Biometrics; 2020 Sep; 76(3):1036-1038. PubMed ID: 31823345
[TBL] [Abstract][Full Text] [Related]
9. Mixed Models for Repeated Measures Should Include Time-by-Covariate Interactions to Assure Power Gains and Robustness Against Dropout Bias Relative to Complete-Case ANCOVA.
Schuler A
Ther Innov Regul Sci; 2022 Jan; 56(1):145-154. PubMed ID: 34674187
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials.
Mallinckrodt CH; Raskin J; Wohlreich MM; Watkin JG; Detke MJ
BMC Psychiatry; 2004 Sep; 4():26. PubMed ID: 15355546
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of overall treatment effect in MMRM.
Song T; Dong Q; Sankoh AJ; Molenberghs G
J Biopharm Stat; 2013; 23(6):1281-93. PubMed ID: 24138432
[TBL] [Abstract][Full Text] [Related]
12. Dose-Response Mixed Models for Repeated Measures - a New Method for Assessment of Dose-Response.
Wellhagen GJ; Hamrén B; Kjellsson MC; Åstrand M
Pharm Res; 2020 Jul; 37(8):157. PubMed ID: 32737604
[TBL] [Abstract][Full Text] [Related]
13. Single time point comparisons in longitudinal randomized controlled trials: power and bias in the presence of missing data.
Ashbeck EL; Bell ML
BMC Med Res Methodol; 2016 Apr; 16():43. PubMed ID: 27068578
[TBL] [Abstract][Full Text] [Related]
14. On the multiple imputation variance estimator for control-based and delta-adjusted pattern mixture models.
Tang Y
Biometrics; 2017 Dec; 73(4):1379-1387. PubMed ID: 28407203
[TBL] [Abstract][Full Text] [Related]
15. Consideration of the adaptive randomization allocation ratio in the presence of treatment group heteroscedasticity in clinical trials.
Lu J; Chen YF
J Biopharm Stat; 2022 May; 32(3):511-526. PubMed ID: 35695576
[TBL] [Abstract][Full Text] [Related]
16. Regression analysis for covariate-adaptive randomization: A robust and efficient inference perspective.
Ma W; Tu F; Liu H
Stat Med; 2022 Dec; 41(29):5645-5661. PubMed ID: 36134688
[TBL] [Abstract][Full Text] [Related]
17. A comparison of covariate adjustment approaches under model misspecification in individually randomized trials.
Tackney MS; Morris T; White I; Leyrat C; Diaz-Ordaz K; Williamson E
Trials; 2023 Jan; 24(1):14. PubMed ID: 36609282
[TBL] [Abstract][Full Text] [Related]
18. Analyzing pre-post randomized studies with one post-randomization score using repeated measures and ANCOVA models.
Wan F
Stat Methods Med Res; 2019; 28(10-11):2952-2974. PubMed ID: 30084297
[TBL] [Abstract][Full Text] [Related]
19. An application of the mixed-effects model and pattern mixture model to treatment groups with differential missingness suspected not-missing-at-random.
Gosho M; Maruo K
Pharm Stat; 2021 Jan; 20(1):93-108. PubMed ID: 33249763
[TBL] [Abstract][Full Text] [Related]
20. Robustness of response-adaptive randomization.
Ye X; Hu F; Ma W
Biometrics; 2024 Mar; 80(2):. PubMed ID: 38819309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
